Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264016 | 0.86 | — | — | |
| SCHEMBL15158364 | 0.86 | BLM (0.44) | EPHX2BLMALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL12224197 | 0.82 | L3MBTL1 (0.48) | EPHX2ALDH1A1FAAHPHGDHMGLL | |
| SCHEMBL2739418 | 0.82 | BLM (0.57) | EPHX2BLMALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL20756575 | 0.82 | BLM (0.57) | EPHX2BLMALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL180620 | 0.82 | — | — | |
| SCHEMBL18909246 | 0.81 | EPHX2 (0.47) | EPHX2ALDH1A1MEN1KMT2AEPHX1 | |
| SCHEMBL20221172 | 0.79 | L3MBTL1 (0.60) | MEN1KMT2A | |
| SCHEMBL13187893 | 0.78 | FAAH (0.44) | ALDH1A1FAAHPHGDHMGLLHPGD | |
| SCHEMBL805446 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | claimed |
| CN-118772116-A | 2, 4-Diaryl aminopyrimidine compound and preparation method and application thereof | 南通常佑药业科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-3201277-B1 | DIGITAL FABRICATION OF METALLIC ARTICLES | AGFA GEVAERT (BE) | 2019-02-20 | — | — | EP | disclosed |
| EP-2953943-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-2964617-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
| EP-0252482-A2 | 7-Acyloxy-6-aminoacyloxypolyoxylabdanes, process for their preparation and their use as medicine | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0217372-A2 | Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-08 | — | — | EP | disclosed |
| US-4105763-A | 1-Methyl-2-(phenyl-oxymethyl)-5-nitro-imidazoles | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |
| US-4078086-A | Anthraquinone-bis-amidines and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL23R, IL18 | EPHX2 1611/4885BLM 4537/4885ALDH1A1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.